drugset / Trial / NCT06328725
Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy
RandomizedParallel-groupDouble-blindTreatment
Summary
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Trial to Evaluate the Efficacy and Safety of EN001 in Patients with Duchenne Muscular Dystrophy
Timeline
- Start
- 2024-03
- Primary completion
- 2025-11
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | EN001 | Cell therapy | 500000 cells/kg | Intravenous |
| Comparator | EN001 | Cell therapy | 2.5e+06 cells/kg | Intravenous |